Explore this article's sources with AI
Follow PeptideMethods on Google
TB-500 Side Effects: Evidence Limits
TB-500 has no validated human safety profile, late-stage trials or regulatory label, so precise adverse-event rates cannot be stated responsibly.
Why we wrote this. Search results often invent a conventional side-effect list for TB-500. The direct human evidence does not support one.
In this article (5 sections)
There are no late-stage human trials or regulatory label for the seven-amino-acid fragment identified in products marketed as TB-500. That means there are no reliable rates for common adverse events, rare reactions or boxed warnings. A 2026 orthopaedic review found no controlled human orthopaedic efficacy evidence and no validated long-term safety data for TB-500[1]. Any article that presents a precise TB-500 side-effect percentage is likely borrowing data from a different molecule or an unverified source.
Full-length thymosin beta-4 has been studied in humans in other formulations, including an eye-drop trial, but TB-500 is a distinct fragment with no validated clinical equivalence[1]. Results from full-length thymosin beta-4 can help define research questions. They cannot supply a safety label for TB-500 injections or for grey-market products using that name.
Why no adverse-event table exists
A conventional adverse-event table comes from controlled trials and regulator-reviewed product information. Researchers record events in both treatment and comparison groups, define severity and assess whether an event may be treatment related. Larger exposure databases are needed to detect uncommon harms. TB-500 does not have that evidence base.
The orthopaedic review describes TB-500 as a seven-amino-acid fragment of thymosin beta-4 and reports no validated biological or clinical equivalence between them[1]. It also raises concerns about identity, purity, concentration, sterility and manufacturing consistency in commercial products. Those quality uncertainties can create harms that are not intrinsic effects of the intended peptide.
For example, an injection-site problem could reflect the compound, a contaminant, a preparation error or nonsterile handling. Without a verified product and structured monitoring, a report cannot reliably separate those causes. Absence of a formal signal is therefore not evidence of safety.
What full-length thymosin beta-4 trials can tell us
A randomized phase 2 study enrolled 72 people with moderate to severe dry eye and tested a 0.1% ophthalmic solution of full-length thymosin beta-4 for 28 days. The paper reports that no adverse events were observed[2]. Ophthalmic means applied to the eye. This finding is specific to that formulation, population and follow-up period.
It would be wrong to turn that eye-drop result into a claim that injected TB-500 has no side effects. Route of administration changes exposure. The tested molecule was different, the formulation was controlled and the trial was too small to exclude rare events. The study also missed both primary efficacy endpoints, even though it reported differences in some secondary measures.
Other human thymosin beta-4 research in skin, eye and cardiovascular settings likewise does not validate TB-500 safety. A safety conclusion must follow the exact material and route being tested. Similar names are not enough.
Risks that can be described without inventing rates
The best-supported risk statement concerns uncertainty. A person may be exposed to an incorrectly identified or inconsistently concentrated product. Injectable material also introduces sterility and contamination concerns. These are product-quality risks, not a verified list of pharmacological side effects.
A second uncertainty is biological. Full-length thymosin beta-4 is involved in actin-related cell movement and has been studied across wound, inflammatory and vascular processes. The short fragment may not reproduce those actions. If it does have biological activity, the limited human evidence does not map its effects across organs or show how they change with repeated exposure.
Athletes also face nonmedical consequences because antidoping rules address TB-500 separately from clinical approval. Our TB-500 WADA status guide explains that rule. A doping sanction is not a side effect, but it is a material risk for tested athletes.
How to interpret symptoms and safety claims
Online lists commonly name fatigue, headache, flushing or injection-site reactions. Without a traceable trial involving defined TB-500 material, those lists cannot establish frequency or causation. Individual reports may be real experiences, but they cannot show whether TB-500, another substance or a product-quality problem caused the symptom.
Anyone who develops symptoms after using an unapproved injectable product should seek medical advice and tell the clinician exactly what was used, when and from what source. Urgent symptoms such as trouble breathing, severe swelling, chest pain, fainting or signs of a serious infection require urgent medical assessment. This is general harm-reduction information, not a diagnosis.
For a broader review of the compound and its evidence, see the TB-500 peptide page. The Denmark regulatory overview explains why regulatory status and reported side effects are separate questions. A clinician can also report suspected adverse reactions through the relevant national system, even when the exact product is uncertain. Keeping packaging or photographs may help identify what was sold, but it does not make a product safe to reuse.
What we do not know yet
We do not know the incidence of common or rare adverse effects for defined TB-500 in humans. We do not have validated information on repeated exposure, interactions, pregnancy, adolescents, older adults, organ impairment or long-term outcomes. We also lack a regulator-reviewed specification that can be applied to products sold under the name.
The practical conclusion is not that TB-500 is proven dangerous or proven safe. It is that its safety profile is undefined. Precise claims should wait for direct human trials using authenticated material, prespecified adverse-event collection and adequate follow-up.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
What are the most common TB-500 side effects?
Direct human trials have not established a reliable list or frequency of TB-500 side effects. Precise percentages are not supported.
Does TB-500 have a boxed warning?
No regulator-reviewed TB-500 label was identified, so there is no boxed-warning section to cite. That absence should not be interpreted as proof of safety.
Can thymosin beta-4 safety data be applied to TB-500?
Not directly. TB-500 is described as a short fragment, and validated biological or clinical equivalence with full-length thymosin beta-4 has not been shown.
What should someone do after a suspected reaction?
Seek medical advice and disclose the product, timing and source. Severe breathing problems, swelling, chest pain, fainting or signs of serious infection need urgent assessment.
Sources
- [1]Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. 2026. PMID 42937313.Tier 1 · primary↩
- [2]Thymosin beta 4 ophthalmic solution for dry eye: randomized placebo-controlled phase 2 trial. 2015. PMID 26056426.Tier 1 · primary↩
No revisions yet. First published .